Liquidia (LQDA): רווחיות מכירות לפי רווח נקי

Liquidia Corporation (LQDA) cash flows are unstable due to patent litigation. High dependence on external manufacturers impacts the realization margin ratio, which the GURU.Markets platform captures in this chart; the parameter has stabilized at -15.20. Business prospects rely on the launch of Yutrepia and the development of unique drug delivery systems.
פילוחי נתונים אנליטיים מרוכזים עבור Liquidia Technologies (LQDA)

Demand for Liquidia Corporation (LQDA) specialized drugs is inelastic; therefore, the core operating net margin reflects operational cost management efficiency rather than market conditions. This indicator measures the portion of net profit in every dollar of revenue, where stable values confirm the business model's resilience to costs, while a sharp decline signals a risk of capital impairment.